Antibodies
28 September 2013
Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival27 September 2013
FDA Approves New Dosing Option for CSL Behring’s Hizentra®27 September 2013
New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications26 September 2013
Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly’s Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes25 September 2013
Stelara® Receives European Commission Approval for Treatment of Active Psoriatic Arthritis25 September 2013
SIMPONI® Receives European Commission Approval For Treatment Of Moderately To Severely Active Ulcerative Colitis24 September 2013
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma20 September 2013
ImmunoGen, Inc. Announces Positive Regulatory Decisions for Roche’s Kadcyla® in the European Union and Japan19 September 2013
Cangene Awarded Biodefence Contract for Anthrax Immune Globulin (AIGIV) by the U.S. Government19 September 2013
OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer17 September 2013
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer17 September 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen17 September 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)14 September 2013
FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia13 September 2013
Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential13 September 2013
FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer12 September 2013
arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.712 September 2013
Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer10 September 2013
Hospira’s Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in EuropeNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports